Difluprednate

Generic Name
Difluprednate
Brand Names
Durezol
Drug Type
Small Molecule
Chemical Formula
C27H34F2O7
CAS Number
23674-86-4
Unique Ingredient Identifier
S8A06QG2QE
Background

Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti.

Indication

For the treatment of inflammation and pain associated with ocular surgery.

Associated Conditions
Anterior Uveitis (AU), Endogenous Anterior Uveitis, Eye Pain, Ocular Inflammation, Pain of the eye
Associated Therapies
-
Clinical Trials
Related News

Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

First Posted Date
2013-09-11
Last Posted Date
2021-01-13
Lead Sponsor
University of California, San Francisco
Target Recruit Count
9
Registration Number
NCT01939691
Locations
🇮🇳

Aravind Eye Hospital, Pondicherry, Tamil Nadu, India

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)

Phase 3
Completed
Conditions
Inflammation
Interventions
Other: Placebo
Drug: Difluprednate
First Posted Date
2008-02-15
Last Posted Date
2011-07-01
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
120
Registration Number
NCT00616993
Locations
🇺🇸

Eye Associates of Fort Myers, Fort Myers, Florida, United States

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)

Phase 3
Completed
Conditions
Inflammation
Interventions
Drug: Difluprednate
Other: Placebo
First Posted Date
2008-02-15
Last Posted Date
2011-06-30
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
120
Registration Number
NCT00616070
Locations
🇺🇸

Charlotte Eye, Ear, Nose & Throat, Charlotte, North Carolina, United States

Study of Difluprednate in the Treatment of Uveitis

Phase 3
Completed
Conditions
Uveitis
First Posted Date
2007-07-16
Last Posted Date
2008-08-29
Lead Sponsor
Sirion Therapeutics, Inc.
Registration Number
NCT00501579
Locations
🇺🇸

John-Kenyon American Eye Institute, New Albany, Indiana, United States

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)

Phase 3
Completed
Conditions
Inflammation
Interventions
Drug: Placebo
Drug: Difluprednate
First Posted Date
2007-02-01
Last Posted Date
2009-07-02
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
219
Registration Number
NCT00430092
Locations
🇺🇸

Comprehensive Eye Care, Washington, Missouri, United States

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)

Phase 3
Completed
Conditions
Inflammation
Interventions
Drug: Difluprednate
Drug: Placebo
First Posted Date
2007-02-01
Last Posted Date
2009-07-02
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
219
Registration Number
NCT00429923
Locations
🇺🇸

Comprehensive Eye Care, Washington, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy